OncoMatch/Clinical Trials/NCT07353957
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Is NCT07353957 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Petosemtamab + Pembrolizumab for lung cancer - non small cell squamous.
Treatment: Petosemtamab + Pembrolizumab — The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: PD-L1 (CD274) TPS ≥ 50% (TPS ≥ 50%)
PD-L1 TPS ≥ 50%
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-(L)1 inhibitor
Participants who received prior treatment with a PD-(L)1 inhibitor
Cannot have received: systemic chemotherapy
Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for metastatic NSCLC
Cannot have received: targeted therapy
Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for metastatic NSCLC
Cannot have received: biological antineoplastic therapy
Participants who have received prior systemic chemotherapy, targeted or biological antineoplastic therapy for metastatic NSCLC
Cannot have received: systemic anticancer therapy
Any systemic anticancer therapy within 4 weeks prior to the first dose of study treatment
Cannot have received: radiotherapy
Exception: Participants who received prior radiotherapy to ≥ 25% of bone marrow are not eligible, regardless of when it was received.
Major surgery or radiotherapy within 3 weeks prior to the first dose of study treatment. Participants who received prior radiotherapy to ≥ 25% of bone marrow are not eligible, regardless of when it was received.
Lab requirements
Blood counts
adequate hematologic function
Kidney function
creatinine clearance ≥ 60 ml/min calculated according to the cockroft and gault formula
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Tennessee Site 2 · Chattanooga, Tennessee
- Tennessee Site 1 · Nashville, Tennessee
- Virginia Site 1 · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify